Efficacy and safety of etanercept in chronic immune-mediated disease

Efficacy and Safety of Leflunomide or Methotrexate plus Subcutaneous Tumour Necrosis Factor-Alpha Blocking Agents in Rheumatoid Arthritis

(2017) M. Benucci et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome

(2014) Nobuyuki Takahashi et al.   Modern Rheumatology

Etanercept for the treatment of intractable hemophagocytic syndrome with systemic lupus erythematosus

(2014) Hirotoshi Kikuchi et al.   Modern Rheumatology

Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naive patients with rheumatoid arthritis

(2014) Takahiko Wada et al.   Modern Rheumatology

Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan

(2014) Masaaki Mori et al.   Modern Rheumatology

Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly

(2014) Takeshi Mochizuki et al.   Modern Rheumatology

Interleukin-17A+ Cell Counts Are Increased in Systemic Sclerosis Skin and Their Number Is Inversely Correlated With the Extent of Skin Involvement

(2013) Marie-Elise Truchetet et al.   ARTHRITIS AND RHEUMATISM

Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity

(2013) Giuseppe Murdaca et al.   AUTOIMMUNITY REVIEWS

Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients

(2013) Joaquín Borrás-Blasco et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis

(2013) Giuseppe Murdaca et al.   Expert Opinion On Drug Safety

Selective TNF-α inhibitor-induced injection site reactions

(2013) Giuseppe Murdaca et al.   Expert Opinion On Drug Safety

Effects of TNF-α inhibitors upon the mechanisms of action of VEGF

(2013) Giuseppe Murdaca et al.   Immunotherapy

Safety of Rituximab in Combination with Other Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: An Open-label Study

(2013) W. F. C. Rigby et al.   JOURNAL OF RHEUMATOLOGY

Free radicals and endothelial dysfunction: Potential positive effects of TNF-α inhibitors

(2013) Giuseppe Murdaca et al.   REDOX REPORT

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data

(2013) C. L. Morgan et al.   RHEUMATOLOGY

Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis

(2013) D van der Heijde et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Endothelial dysfunction in rheumatic autoimmune diseases

(2012) Giuseppe Murdaca et al.   ATHEROSCLEROSIS

Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: A retrospective analysis of 49 cases

(2012) Han Hee Ryu et al.   CLINICAL RHEUMATOLOGY

Therapeutic advances in myositis

(2012) Rohit Aggarwal et al.   CURRENT OPINION IN RHEUMATOLOGY

Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study

(2012) Maria Esposito et al.   DERMATOLOGY

Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis

(2012) Giampiero Girolomoni et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Determination of Lymphotoxin-Alpha Levels in Patients with Psoriatic Arthritis Undergoing Etanercept Treatment

(2012) Giuseppe Murdaca et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists

(2012) Gulen Hatemi et al.   ARTHRITIS RESEARCH & THERAPY

Leucopenia e trombocitopenia induzidas por etanercepte: relato de dois casos e revisão da literatura

(2012) Valderílio Feijó Azevedo et al.   Revista Brasileira De Reumatologia

Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events

(2011) Giuseppe Murdaca et al.   AUTOIMMUNITY REVIEWS

The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis

(2011) Soner Senel et al.   CLINICAL RHEUMATOLOGY

Update upon efficacy and safety of TNF-α inhibitors

(2011) Giuseppe Murdaca et al.   Expert Opinion On Drug Safety

The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases

(2011) Giuseppe Murdaca et al.   Internal and Emergency Medicine

Anti-Tumor Necrosis Factor-α Treatment with Infliximab for Disseminated Granuloma Annulare

(2010) Giuseppe Murdaca et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Lymphoma, rheumatoid arthritis, and TNFα antagonists

(2010) Xavier Mariette   JOINT BONE SPINE

Biologic Therapy for Systemic Sclerosis: A Systematic Review

(2010) V. PHUMETHUM et al.   JOURNAL OF RHEUMATOLOGY

Anti-TNF Agents for Behçet's Disease: Analysis of Published Data on 369 Patients

(2010) Aikaterini Arida et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

(2009) O Kowal-Bielecka et al.   ANNALS OF THE RHEUMATIC DISEASES

The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease

(2009) M. J. Shale   BRITISH MEDICAL BULLETIN

Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFα blockers: Safety and immunogenicity

(2009) S. Salemi et al.   CLINICAL IMMUNOLOGY

Targeted depletion of lymphotoxin-α–expressing TH1 and TH17 cells inhibits autoimmune disease

(2009) Eugene Y Chiang et al.   NATURE MEDICINE

Vascular effects of biologic agents in RA and spondyloarthropathies

(2009) Zoltán Szekanecz et al.   Nature Reviews Rheumatology

Serum vascular endothelial growth factor and sublingual immunotherapy

(2008) G. Ciprandi et al.   ALLERGY

Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study

(2008) B Combe et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases

(2008) I. Cavazzana et al.   AUTOIMMUNITY REVIEWS

Traditional and non traditional risk factors in accelerated atherosclerosis in Systemic Lupus Erythematosus: Role of vascular endothelial growth factor (VEGATS Study)

(2008) Barbara Maria Colombo et al.   AUTOIMMUNITY REVIEWS

Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus

(2008) Giorgio Ciprandi et al.   HUMAN IMMUNOLOGY

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alice Gottlieb et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Successful Etanercept Therapy for Refractory Sacroiliitis in a Patient with Ankylosing Spondylitis and Mixed Connective Tissue Disease

(2008) Jee Young Lee et al.   YONSEI MEDICAL JOURNAL